RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Alzheimer DiseaseMild Cognitive ImpairmentCognitive Decline
Interventions
DRUG

Resveratrol, Quercetin, and Curcumin (RQC)

"2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)"

DRUG

Curcumin

2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.

Trial Locations (1)

60611

Zaparackas & Knepper Ltd., Chicago

All Listed Sponsors
collaborator

Northwestern University Feinberg School of Medicine

OTHER

lead

Zaparackas and Knepper LTD

OTHER